Blaze Bioscience Inc. Appoints Jan Öhrström, M.D., To Its Board Of Directors

SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that Jan Öhrström, M.D., a biotechnology executive with over 20 years of industry experience, has been appointed to the company's Board of Directors.

Dr. Öhrström brings to the Board his expertise in developing and commercializing surgical products as well as broad entrepreneurial and operational experience.

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.